AbbVie’s promising oral hepatitis C combo treatment is rolling along toward FDA approval, and the drugmaker unveiled a deeper set of Phase III data in which the cocktail cured nearly 100% of patients in a tough-to-treat population.

…read more

Source: AbbVie’s hep C cocktail aces its latest PhIII study with a sky-high cure rate


0 No comments